Iterum Therapeutics plc plans to launch ORLYNVAHTM this month, a new antibiotic for uncomplicated urinary tract infections. The company expects the launch in August 2025, targeting patients with limited treatment options due to resistant bacteria. Financial results show a cash runway into 2026. A conference call will be held today at 8:30amET.

Iterum has entered partnerships and agreements for commercialization, manufacturing, and supply of ORLYNVAHTM. The company has also expanded its patent estate and published results from a Phase 3 clinical trial. Pfizer agreed to extend debt repayment to 2029. Financial results for Q2 2025 show costs, expenses, and a net loss.

Key financial figures for Q2 2025 include cash and cash equivalents of $13.0 million, with a net loss of $6.5 million. Research and development expenses decreased, while general and administrative expenses increased. Non-GAAP net loss for Q2 2025 was $5.1 million. A conference call will provide further details on financial performance.

Iterum Therapeutics plc aims to combat multi-drug resistant pathogens with its anti-infective compounds. The company’s first compound, sulopenem, has received FDA approval for ORLYNVAHTM. Iterum is focused on improving the lives of those affected by serious infections. Forward-looking statements highlight the company’s plans, strategies, and market potential.

Read more at GlobeNewswire: Iterum Therapeutics Reports Second Quarter 2025 Financial